graves-disease
(2)
Adam Townsend
He spent two decades launching other people's medicines. Now he is running a biotech built to delete the antibodies that make patients sick - and taking the top job for the first time.
Merida Biosciences
Merida Biosciences is a Cambridge, Massachusetts biotechnology company developing a new class of engineered Fc biotherapeutics that selectively bind and eliminate the disease-causing antibodies behind autoimmune and allergic diseases, while sparing the protective antibodies the immune system needs. Launched publicly in April 2025 with a $121 million Series A, the company aims to treat conditions such as Graves' disease, IgE-mediated allergy and primary membranous nephropathy by clearing pathogenic antibodies and suppressing the B cells that make them - without the broad immunosuppression that limits many existing therapies.